PM
MCID: PLY041
MIFTS: 58

Polymyositis (PM)

Categories: Bone diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Polymyositis

MalaCards integrated aliases for Polymyositis:

Name: Polymyositis 53 54 59 55 73
Pm 59

Characteristics:

Orphanet epidemiological data:

59
polymyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Argentina),1-9/100000 (Argentina),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Spain),1-9/1000000 (Sweden); Age of onset: Adult,Elderly; Age of death: adult;

Classifications:



Summaries for Polymyositis

NINDS : 54 Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Polymyositis affects skeletal muscles (those involved with making movement) on both sides of the body.  It is rarely seen in persons under age 18; most cases are in adults between the ages of 31 and 60.  Progressive muscle weakness starts in the proximal muscles (muscles closest to the trunk of the body) which eventually leads to difficulties climbing stairs, rising from a seated position, lifting objects, or reaching overhead.  People with polymyositis may also experience arthritis, shortness of breath, difficulty swallowing and speaking, and heart arrhythmias.  In some cases of polymyositis, distal muscles (muscles further away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Polymyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus.  Polymyositis may also be associated with infectious disorders, such as HIV-AIDS.

MalaCards based summary : Polymyositis, also known as pm, is related to dermatomyositis and inclusion body myositis. An important gene associated with Polymyositis is RN7SL1 (RNA, 7SL, Cytoplasmic 1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Pirfenidone and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and t cells, and related phenotypes are muscular hypotonia and gait disturbance

NIH Rare Diseases : 53 Polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. The muscles affected by polymyositis are the skeletal muscles (those involved with making movements) on both sides of the body. Although the disease can affect people of all ages, most cases are seen in adults between the ages of 31 and 60 years. The disease is more common among women and among black individuals.  The exact cause of polymyositis is unknown. The disease shares many characteristics with autoimmune disorders, which occur when the immune system mistakenly attacks healthy body tissues. In some cases, the disease may be associated with viral infections, connective tissue disorders, or an increased risk for malignancies (cancer). Diagnosis is based on a clinical examination that may include laboratory tests, imaging studies, electromyography, and a muscle biopsy. Although there is no cure for polymyositis, treatment with corticosteroids or immunosuppressants can improve muscle strength and function.

Wikipedia : 76 Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to... more...

Related Diseases for Polymyositis

Diseases in the Polymyositis family:

Juvenile Polymyositis

Diseases related to Polymyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 305)
# Related Disease Score Top Affiliating Genes
1 dermatomyositis 30.2 MIR130A MIR132 MIR146B MIR155 MIR21 MIR210
2 inclusion body myositis 29.9 MIR146B MIR155 MIR21 MIR214 MIR222
3 diffuse large b-cell lymphoma 29.0 MIR127 MIR155 MIR21 MIR210
4 miyoshi muscular dystrophy 1 28.9 MIR132 MIR146B MIR382
5 leukemia, acute lymphoblastic 28.9 MIR130A MIR155 MIR21 MIR210 MIR222
6 pancreatic cancer 28.8 MIR127 MIR155 MIR21 MIR210 MIR214 MIR222
7 hepatocellular carcinoma 28.8 MIR127 MIR130A MIR132 MIR155 MIR21 MIR214
8 muscular dystrophy, duchenne type 28.6 MIR127 MIR130A MIR146B MIR21 MIR210 MIR214
9 lung cancer 28.5 MIR130A MIR146B MIR155 MIR21 MIR210 MIR214
10 ovarian cancer 28.3 MIR127 MIR146B MIR155 MIR21 MIR210 MIR214
11 juvenile polymyositis 12.6
12 myositis 11.6
13 mixed connective tissue disease 11.6
14 childhood type dermatomyositis 11.5
15 idiopathic inflammatory myopathy 11.3
16 myelopathy, htlv-1-associated 11.3
17 tropical spastic paraparesis 11.3
18 antisynthetase syndrome 11.3
19 necrotizing autoimmune myopathy 11.3
20 retrovirus-associated myelopathy 11.0
21 lung disease 10.5
22 interstitial lung disease 10.5
23 pneumonia 10.3
24 scleroderma, familial progressive 10.3
25 myopathy 10.3
26 arthritis 10.2
27 hepatitis 10.2
28 rheumatoid arthritis 10.2
29 myocarditis 10.2
30 myasthenia gravis 10.2
31 thymoma 10.2
32 lupus erythematosus 10.2
33 myasthenia gravis congenital 10.2
34 connective tissue disease 10.1
35 systemic lupus erythematosus 10.1
36 graft-versus-host disease 10.1
37 lymphoma 10.1
38 chronic graft versus host disease 10.1
39 muscular dystrophy 10.1
40 leukemia 10.0
41 adult dermatomyositis 10.0
42 hypothyroidism 10.0
43 fasciitis 10.0
44 glomerulonephritis 10.0
45 respiratory failure 10.0
46 purpura 10.0
47 breast cancer 10.0
48 autoimmune hepatitis 10.0
49 hepatitis b 10.0
50 hepatitis c 10.0

Comorbidity relations with Polymyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Dermatomyositis Heart Disease
Hypertension, Essential Hypothyroidism
Osteoporosis Temporal Arteritis

Graphical network of the top 20 diseases related to Polymyositis:



Diseases related to Polymyositis

Symptoms & Phenotypes for Polymyositis

Human phenotypes related to Polymyositis:

59 32 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscular hypotonia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001252
2 gait disturbance 59 32 occasional (7.5%) Occasional (29-5%) HP:0001288
3 dysphonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001618
4 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
5 respiratory insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002093
6 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
7 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
8 gastroesophageal reflux 59 32 occasional (7.5%) Occasional (29-5%) HP:0002020
9 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
10 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
11 pulmonary fibrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002206
12 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
13 hypertrophic cardiomyopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001639
14 elevated serum creatine phosphokinase 59 32 hallmark (90%) Very frequent (99-80%) HP:0003236
15 emg abnormality 59 32 hallmark (90%) Very frequent (99-80%) HP:0003457
16 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
17 myocardial infarction 59 32 occasional (7.5%) Occasional (29-5%) HP:0001658
18 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
19 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
20 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
21 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
22 venous thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004936
23 dilated cardiomyopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001644
24 reduced tendon reflexes 59 32 occasional (7.5%) Occasional (29-5%) HP:0001315
25 abnormality of the renal tubule 59 32 occasional (7.5%) Occasional (29-5%) HP:0000091
26 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
27 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
28 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
29 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
30 cough 59 32 hallmark (90%) Very frequent (99-80%) HP:0012735
31 vasculitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002633
32 breast carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0003002
33 proximal muscle weakness 59 32 hallmark (90%) Very frequent (99-80%) HP:0003701
34 elevated aldolase level 59 32 hallmark (90%) Very frequent (99-80%) HP:0012544
35 abnormality of muscle fibers 59 32 hallmark (90%) Very frequent (99-80%) HP:0004303
36 chondrocalcinosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000934
37 abnormal atrioventricular conduction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005150
38 exertional dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002875
39 interstitial pulmonary abnormality 59 32 frequent (33%) Frequent (79-30%) HP:0006530
40 abnormality of the voice 59 Occasional (29-5%)
41 abnormality of the mitral valve 59 Occasional (29-5%)
42 abnormal mitral valve morphology 32 occasional (7.5%) HP:0001633

Drugs & Therapeutics for Polymyositis

Drugs for Polymyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
2
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
3 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Vaccines Phase 4,Phase 2,Not Applicable
11 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 beta-endorphin Phase 4,Phase 2
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Melanocyte-Stimulating Hormones Phase 4,Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Adrenocorticotropic Hormone Phase 4,Phase 2
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18
Prednisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 53-03-2 5865
19
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
21
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
22
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
23
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
24
Methotrexate Approved Phase 3,Phase 2 59-05-2, 1959-05-2 126941
25
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
26
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
27
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
28
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
29 tannic acid Approved Phase 2, Phase 3
30
Infliximab Approved Phase 2, Phase 3 170277-31-3
31
Alendronate Approved Phase 3 66376-36-1, 121268-17-5 2088
32
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 6055-19-2, 50-18-0 2907
33
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
34
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
35
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
36
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
38
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
39
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
40
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
41 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
42 Methylprednisolone acetate Phase 3,Phase 2
43 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Not Applicable
44 Antimetabolites, Antineoplastic Phase 3,Phase 2
45 Calcineurin Inhibitors Phase 3,Phase 2
46 Prednisolone acetate Phase 3,Phase 2
47 Vitamin B9 Phase 3,Phase 2
48 Cyclosporins Phase 3,Phase 2
49 Vitamin B Complex Phase 3,Phase 2
50 Antifungal Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 94)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
4 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
5 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
6 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
7 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
8 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
9 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
10 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
11 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
12 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
13 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
14 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
15 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
16 Belimumab in Idiopathic Inflammatory Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
17 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Recruiting NCT03813160 Phase 3 Lenabasum 20 mg;Lenabasum 5 mg;Placebo
18 Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis Recruiting NCT03686969 Phase 3 Octanorm
19 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Active, not recruiting NCT02728752 Phase 3 Octagam 10%
20 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
21 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
22 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
23 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
24 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
25 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
26 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
27 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
28 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
29 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
30 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
31 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
32 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
33 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
34 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
35 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Recruiting NCT03529955 Phase 2 Apremilast 30mg
36 A Study In Adults With Moderate To Severe Dermatomyositis Recruiting NCT03181893 Phase 2 PF-06823859;Placebo Arm
37 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
38 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
39 Trial of IMO-8400 in Adult Patients With Dermatomyositis Active, not recruiting NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
40 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Active, not recruiting NCT02466243 Phase 2 JBT-101;Placebo
41 Basiliximab Treating Interstitial Pneumonia of CADM Not yet recruiting NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
42 Intralesional Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study Not yet recruiting NCT03582800 Phase 2 STS
43 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
44 Efficacy and Tolerability of BAF312 in Patients With Polymyositis Terminated NCT01801917 Phase 2 Placebo;BAF312
45 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
46 Safety and Efficacy of BAF312 in Dermatomyositis Terminated NCT02029274 Phase 2 BAF312;Placebo
47 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
48 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
49 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Completed NCT02780674 Phase 1
50 Mycophenolate Mofetil in Systemic Sclerosis Completed NCT00433186 Phase 1 Mycophenolate Mofetil

Search NIH Clinical Center for Polymyositis

Genetic Tests for Polymyositis

Anatomical Context for Polymyositis

MalaCards organs/tissues related to Polymyositis:

41
Lung, Heart, T Cells, Testes, Skeletal Muscle, Bone, Thyroid

Publications for Polymyositis

Articles related to Polymyositis:

(show top 50) (show all 2125)
# Title Authors Year
1
Integrated comparison of the miRNAome and mRNAome in muscles of dermatomyositis and polymyositis reveals common and specific miRNA-mRNAs. ( 30523707 )
2019
2
The traffic signature on the vertical PM profile: Environmental and health risks within an urban roadside environment. ( 30055502 )
2019
3
Effectiveness of commercial face masks to reduce personal PM exposure. ( 30308844 )
2019
4
Using multi-site data to apportion PM-bound metal(loid)s: Impact of a manganese alloy plant in an urban area. ( 30360277 )
2019
5
Tofacitinib for the Treatment of Refractory Polymyositis. ( 29794877 )
2018
6
The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. ( 29977547 )
2018
7
Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis. ( 29720222 )
2018
8
A patient with pembrolizumab-induced fatal polymyositis. ( 29329695 )
2018
9
[<sup>18</sup>F]Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing polymyositis/dermatomyositis. ( 29805526 )
2018
10
Roles of macrophage migration inhibitory factor in polymyositis: Inflammation and regeneration. ( 29239244 )
2018
11
Coexistence of anti-Jo1 and anti-signal recognition particle antibodies in a polymyositis patient. ( 29396013 )
2018
12
Symptomatic arrhythmia in the form of multiple premature ventricular extrasystoles as the first symptom of polymyositis. ( 29380919 )
2018
13
Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. ( 29293605 )
2018
14
Malignancy in a retrospective cohort of 17 patients with Dermatomyositis or Polymyositis in southern Tunisia. ( 29791319 )
2018
15
Respiratory insufficiency from myasthenia gravis and polymyositis due to malignant thymoma triggering Takotsubo syndrome. ( 29883223 )
2018
16
Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients With Polymyositis/Dermatomyositis. ( 29933322 )
2018
17
The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ( 29325580 )
2018
18
Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process? ( 29850899 )
2018
19
Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. ( 29321815 )
2018
20
Autologous Bone Marrow Transplantation for Polymyositis Combined with Myasthenia Gravis and Aplastic Anemia: A Case Report. ( 29805377 )
2018
21
Hyaluronic acid in dermatomyositis and polymyositis: relationship with disease and cutaneous lesions. ( 29641701 )
2018
22
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. ( 28993346 )
2018
23
Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases. ( 29657141 )
2018
24
Pure erythroid leukemia in a polymyositis patient treated with azathioprine. ( 29785257 )
2018
25
Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis. ( 29496919 )
2018
26
MicroRNA-381 reduces inflammation and infiltration of macrophages in polymyositis via downregulating HMGB1. ( 29956737 )
2018
27
A Viral Polymyositis Masquerade: Life-Threatening Case of Juvenile Dermatomyositis Complicated by Systemic Capillary Leak Syndrome. ( 29720802 )
2018
28
Musculoskeletal Manifestations of Non-RA Connective Tissue Diseases: Scleroderma, Systemic Lupus Erythematosus, Still's Disease, Dermatomyositis/Polymyositis, SjAPgren's Syndrome, and Mixed Connective Tissue Disease. ( 29672805 )
2018
29
Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. ( 29027009 )
2018
30
Limb-girdle muscular dystrophy type 2B misdiagnosed as polymyositis at the early stage: Case report and literature review. ( 29794729 )
2018
31
Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis. ( 29416342 )
2018
32
The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. ( 29703532 )
2018
33
Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. ( 29289262 )
2018
34
Current diagnosis and treatment of polymyositis and dermatomyositis. ( 29669460 )
2018
35
Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: A retrospective case-control study. ( 29474373 )
2018
36
Role of Positron Emission Tomography-computed Tomography in a Case of Suspected Paraneoplastic Inflammatory Polymyositis with Urinary Bladder Tumor. ( 29430120 )
2018
37
Early life exposure to air pollution particulate matter (PM) as risk factor for attention deficit/hyperactivity disorder (ADHD): Need for novel strategies for mechanisms and causalities. ( 29550511 )
2018
38
Polymyositis as a manifestation of chronic graft-versus-host disease after allo-HSCT. ( 30214750 )
2018
39
Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis/dermatomyositis. ( 30292269 )
2018
40
KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker. ( 30484723 )
2018
41
Raynaud's phenomenon and anti-nuclear antibody are associated with pulmonary function decline in patients with dermatomyositis and polymyositis. ( 30548402 )
2018
42
Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis. ( 30019588 )
2018
43
Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis. ( 30053824 )
2018
44
Thrombotic Microangiopathy with Polymyositis/Dermatomyositis: Three Case Reports and a Literature Review. ( 30068898 )
2018
45
Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment. ( 30102381 )
2018
46
STROBE: The correlation of Cyr61, CTGF, and VEGF with polymyositis/dermatomyositis. ( 30142763 )
2018
47
Association between the BANK1 rs3733197 polymorphism and polymyositis/dermatomyositis in a Chinese Han population. ( 30145638 )
2018
48
T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients. ( 30157932 )
2018
49
T2 mapping in dermatomyositis/polymyositis and correlation with clinical parameters. ( 30172348 )
2018
50
Corneal Involvement of Patients with Polymyositis and Dermatomyositis. ( 30444429 )
2018

Variations for Polymyositis

Expression for Polymyositis

Search GEO for disease gene expression data for Polymyositis.

Pathways for Polymyositis

Pathways related to Polymyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.5 MIR155 MIR21 MIR210 MIR214 MIR222
2 10.85 MIR210 MIR222
3 10.54 MIR146B MIR222

GO Terms for Polymyositis

Cellular components related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 MIR127 MIR130A MIR132 MIR146B MIR155 MIR21
2 micro-ribonucleoprotein complex GO:0035068 9.4 MIR127 MIR130A MIR132 MIR146B MIR155 MIR21

Biological processes related to Polymyositis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.78 MIR132 MIR155 MIR21 MIR214
2 positive regulation of protein kinase B signaling GO:0051897 9.75 MIR132 MIR21 MIR222
3 negative regulation of angiogenesis GO:0016525 9.7 MIR21 MIR214 MIR222
4 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.62 MIR146B MIR155
5 positive regulation of epithelial to mesenchymal transition GO:0010718 9.61 MIR21 MIR222
6 negative regulation of blood vessel endothelial cell migration GO:0043537 9.61 MIR132 MIR155
7 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.6 MIR214 MIR222
8 positive regulation of activated T cell proliferation GO:0042104 9.59 MIR155 MIR21
9 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.58 MIR155 MIR222
10 positive regulation of cardiac muscle hypertrophy GO:0010613 9.57 MIR155 MIR21
11 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.56 MIR21 MIR214
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.56 MIR130A MIR21 MIR214 MIR222
13 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.55 MIR155 MIR222
14 positive regulation of angiogenesis GO:0045766 9.55 MIR130A MIR132 MIR21 MIR210 MIR99B
15 positive regulation of endothelial cell differentiation GO:0045603 9.54 MIR21 MIR99B
16 positive regulation of connective tissue replacement GO:1905205 9.51 MIR155 MIR214
17 positive regulation of vascular endothelial cell proliferation GO:1905564 9.5 MIR130A MIR132 MIR21
18 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.49 MIR155 MIR214
19 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.46 MIR21 MIR210
20 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.43 MIR155 MIR222
21 negative regulation of regulatory T cell differentiation GO:0045590 9.4 MIR155 MIR21
22 gene silencing by miRNA GO:0035195 9.4 MIR127 MIR130A MIR132 MIR146B MIR155 MIR21
23 negative regulation of cell adhesion molecule production GO:0060354 9.37 MIR155 MIR222
24 miRNA mediated inhibition of translation GO:0035278 9.35 MIR132 MIR155 MIR21 MIR210 MIR222

Molecular functions related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR130A MIR132 MIR146B MIR155 MIR21 MIR210

Sources for Polymyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....